Rare Clonal Myeloid Diseases

  • Thomas Melchardt
  • Lukas Weiss
  • Lisa Pleyer
  • Daniel Neureiter
  • Victoria Faber
  • Richard Greil


The “classical” myeloproliferative neoplasms such as essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF) and chronic myeloid leukemia (CML) are relatively rare disorders. Due to the long life span of most patients with these diseases however, the prevalence is quite high, so that patients with these diseases are commonly seen in hematological outpatient departments.


Mast Cell Systemic Mastocytosis Hypereosinophilic Syndrome Histiocytic Sarcoma Sinus Histiocytosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Wolff K, Komar M, Petzelbauer P (2001) Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25: 519–528PubMedGoogle Scholar
  2. [2]
    Flageul B (2006) Cutaneous mastocytosis. Rev Prat 56: 1745–1751PubMedGoogle Scholar
  3. [3]
    Lawrence JB, Friedman BS, Travis WD, Chinchilli VM, Metcalfe DD, Gralnick HR (1991) Hematologic manifestations of systemic mast-cell disease — a prospective-study of laboratory and morphological features and their relation to prognosis. Am J Med 91: 612–624PubMedGoogle Scholar
  4. [4]
    Escribano L, Alvarez-Twose I, Sanchez-Munoz L et al. (2009) Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 124: 514–521PubMedGoogle Scholar
  5. [5]
    Lim KH, Tefferi A, Lasho TL et al. (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113: 5727–5736PubMedGoogle Scholar
  6. [6]
    Valent P (2008) Systemic mastocytosis. Cancer Treat Res 142: 399–419PubMedGoogle Scholar
  7. [7]
    Castells M, Austen KF (2002) Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol 127: 147–152PubMedGoogle Scholar
  8. [8]
    Kawakami T, Galli SJ (2002) Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2: 773–786PubMedGoogle Scholar
  9. [9]
    Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31: 185–205PubMedGoogle Scholar
  10. [10]
    Gilfillan AM, Tkaczyk C (2006) Integrated signalling pathways for mast-cell activation. Nat Rev Immunol 6: 218–230PubMedGoogle Scholar
  11. [11]
    Garcia-Montero AC, Jara-Acevedo M, Teodosio C et al. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108: 2366–2372PubMedGoogle Scholar
  12. [12]
    Vega-Ruiz A, Cortes JE, Sever M et al. (2009) Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res 33: 1481–1484PubMedGoogle Scholar
  13. [13]
    Pardanani A, Elliott M, Reeder T et al. (2003) Imatinib for systemic mast-cell disease. Lancet 362: 535–536PubMedGoogle Scholar
  14. [14]
    Valent P, Horny HP, Escribano L et al. (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603–625PubMedGoogle Scholar
  15. [15]
    Metcalfe DD (2008) Mast cells and mastocytosis. Blood 112: 946–956PubMedGoogle Scholar
  16. [16]
    Escribano L, Akin C, Castells M, Orfao A, Metcalfe DD (2002) Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 81: 677–690PubMedGoogle Scholar
  17. [17]
    Swerdlow SH, Campo E, Harris NL et al. (eds) (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, LyonGoogle Scholar
  18. [18]
    Mathew R, Dhillon V, Shepherd P (2009) Systemic mastocytosis presenting as osteoporosis — a case report. Clin Rheumatol 28: 865–866PubMedGoogle Scholar
  19. [19]
    Delling G, Ritzel H, Werner M (2001) Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases. Pathologe 22: 132–140PubMedGoogle Scholar
  20. [20]
    Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36: 32–36PubMedGoogle Scholar
  21. [21]
    Yam LT, Yam CF, Li CY (1980) Eosinophilia in systemic mastocytosis. Am J Clin Pathol 73: 48–54PubMedGoogle Scholar
  22. [22]
    Miranda RN, Esparza AR, Sambandam S, Medeiros LJ (1994) Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol 25: 727–730PubMedGoogle Scholar
  23. [23]
    Klion AD, Robyn J, Akin C et al. (2004) Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473–478PubMedGoogle Scholar
  24. [24]
    Florian S, Esterbauer H, Binder T et al. (2006) Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFR-α, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 30: 1201–1205PubMedGoogle Scholar
  25. [25]
    Valent P, Akin C, Escribano L et al. (2007) Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37: 435–453PubMedGoogle Scholar
  26. [26]
    Bowers HM Jr, Mahapatro RC, Kennedy JW (1979) Numbers of mast cells in the axillary lymph nodes of breast cancer patients. Cancer 43: 568–573PubMedGoogle Scholar
  27. [27]
    Yoo D, Lessin LS, Jensen WN (1978) Bone-marrow mast cells in lymphoproliferative disorders. Ann Intern Med 88: 753–757PubMedGoogle Scholar
  28. [28]
    Bridges AJ, Malone DG, Jicinsky J et al. (1991) Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and antirheumatic therapy. Arthritis Rheum 34: 1116–1124PubMedGoogle Scholar
  29. [29]
    Lennert K, Parwaresch MR (1979) Mast cells and mast cell neoplasia: a review. Histopathology 3: 349–365PubMedGoogle Scholar
  30. [30]
    Brockow K, Jofer C, Behrendt H, Ring J (2008) Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 63: 226–232PubMedGoogle Scholar
  31. [31]
    Metcalfe DD (1991) The treatment of mastocytosis: an overview. J Invest Dermatol 96: 55S–56SGoogle Scholar
  32. [32]
    Valent P, Akin C, Sperr WR et al. (2003) Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27: 635–641PubMedGoogle Scholar
  33. [33]
    Simon J, Lortholary O, Caillat-Vigneron N et al. (2004) Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris) 52: 294–299Google Scholar
  34. [34]
    Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A (2004) Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28: 127–131PubMedGoogle Scholar
  35. [35]
    Lim AY, Ostor AJ, Love S, Crisp AJ (2005) Systemic mastocytosis: a rare cause of osteoporosis and its response to bisphosphonate treatment. Ann Rheum Dis 64: 965–966PubMedGoogle Scholar
  36. [36]
    Tefferi A (2005) Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 80: 75–83PubMedGoogle Scholar
  37. [37]
    Hardy WR, Anderson RE (1968) The hypereosinophilic syndromes. Ann Intern Med 68: 1220–1229PubMedGoogle Scholar
  38. [38]
    Weller PF, Bubley GJ (1994) The idiopathic hypereosinophilic syndrome. Blood 83: 2759–2779PubMedGoogle Scholar
  39. [39]
    Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM (2000) Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161: 1720–1745PubMedGoogle Scholar
  40. [40]
    Ogbogu PU, Rosing DR, Horne MK III (2007) Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 27: 457–475PubMedGoogle Scholar
  41. [41]
    Chao CC, Hsieh ST, Shun CT, Hsieh SC (2007) Skin denervation and cutaneous vasculitis in eosinophiliaassociated neuropathy. Arch Neurol 64: 959–965PubMedGoogle Scholar
  42. [42]
    Tefferi A, Patnaik MM, Pardanani A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133: 468–492PubMedGoogle Scholar
  43. [43]
    Valent P (2009) Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 23: 157–165PubMedGoogle Scholar
  44. [44]
    Parrillo JE, Fauci AS, Wolff SM (1978) Therapy of the hypereosinophilic syndrome. Ann Intern Med 89: 167–172PubMedGoogle Scholar
  45. [45]
    Butterfield JH, Gleich GJ (1994) Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med 121: 648–653PubMedGoogle Scholar
  46. [46]
    Yoon TY, Ahn GB, Chang SH (2000) Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol 27: 110–115PubMedGoogle Scholar
  47. [47]
    Pardanani A, Brockman SR, Paternoster SF et al. (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 104: 3038–3045PubMedGoogle Scholar
  48. [48]
    Sefcick A, Sowter D, DasGupta E, Russell NH, Byrne JL (2004) Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol 124: 558–559PubMedGoogle Scholar
  49. [49]
    Bain BJ, Fletcher SH (2007) Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 27: 377–388PubMedGoogle Scholar
  50. [50]
    Fletcher S, Bain B (2007) Diagnosis and treatment of hypereosinophilic syndromes. Curr Opin Hematol 14: 37–42PubMedGoogle Scholar
  51. [51]
    Gotlib J, Cools J (2008) Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22: 1999–2010PubMedGoogle Scholar
  52. [52]
    Cools J, DeAngelo DJ, Gotlib J et al. (2003) Atyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201–1214PubMedGoogle Scholar
  53. [53]
    Lierman E, Michaux L, Beullens E et al. (2009) FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFR-α T674I eosinophilic leukemia with single agent sorafenib. Leukemia 23: 845–851PubMedGoogle Scholar
  54. [54]
    Score J, Curtis C, Waghorn K et al. (2006) Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 20: 827–832PubMedGoogle Scholar
  55. [55]
    Walz C, Curtis C, Schnittger S et al. (2006) Transient response to imatinib in a chronic eosinophilic leukemia associated with ins (9;4) (q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer 45: 950–956PubMedGoogle Scholar
  56. [56]
    Baxter EJ, Hochhaus A, Bolufer P et al. (2002) The t (4;22) (q12;q11) in atypical chronic myeloid leukemia fuses BCR to PDGFRA. Hum Mol Genet 11: 1391–1397PubMedGoogle Scholar
  57. [57]
    Steer EJ, Cross NC (2002) Myeloproliferative disorders with translocations of chromosome 5q31–35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 107: 113–122PubMedGoogle Scholar
  58. [58]
    Macdonald D, Reiter A, Cross NC (2002) The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 107: 101–107PubMedGoogle Scholar
  59. [59]
    Vandenberghe P, Wlodarska I, Michaux L et al. (2004) Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 18: 734–742PubMedGoogle Scholar
  60. [60]
    Pardanani A, Reeder T, Porrata LF et al. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101: 3391–3397PubMedGoogle Scholar
  61. [61]
    Gleich GJ, Leiferman KM (2009) The hypereosinophilic syndromes: current concepts and treatments. Br J Haematol 145: 271–285PubMedGoogle Scholar
  62. [62]
    von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J (2006) The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood 107: 4970–4971Google Scholar
  63. [63]
    Fletcher S, Bain B (2007) Eosinophilic leukemia. Br Med Bull 81–82: 115–127PubMedGoogle Scholar
  64. [64]
    Wittig HJ, Belloit J, De FI, Royal G (1980) Age-related serum immunoglobulin E levels in healthy subjects and in patients with allergic disease. J Allergy Clin Immunol 66: 305–313PubMedGoogle Scholar
  65. [65]
    Brigden ML (1999) A practical workup for eosinophilia. You can investigate the most likely causes right in your office. Postgrad Med 105: 193–202, 207PubMedGoogle Scholar
  66. [66]
    Ben m’rad M, Leclerc-Mercier S, Blanche P et al. (2009) Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 88: 131–140Google Scholar
  67. [67]
    Mockenhaupt M (2009) Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 7: 142–160PubMedGoogle Scholar
  68. [68]
    Ghislain PD, Roujeau JC (2002) Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 8: 5PubMedGoogle Scholar
  69. [69]
    Masi AT, Hunder GG, Lie JT et al. (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33: 1094–1100PubMedGoogle Scholar
  70. [70]
    Varga J, Griffin R, Newman JH, Jimenez SA (1991) Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated with L-tryptophan use. J Rheumatol 18: 259–263PubMedGoogle Scholar
  71. [71]
    Posada, dIP, Philen RM, Borda AI (2001) Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 23: 231–247Google Scholar
  72. [72]
    Sanchez-Porro VP, Posada, dIP, de Andres CP, Gimenez RO, Abaitua BI (2003) Toxic oil syndrome: survival in the whole cohort between 1981 and 1995. J Clin Epidemiol 56: 701–708Google Scholar
  73. [73]
    Gotlib J, Cools J, Malone JM III, Schrier SL, Gilliland DG, Coutre SE (2004) The FIP1L1-PDGFR-α fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 103: 2879–2891PubMedGoogle Scholar
  74. [74]
    Simon HU, Plotz SG, Dummer R, Blaser K (1999) Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341: 1112–1120PubMedGoogle Scholar
  75. [75]
    La Starza R, Trubia M, Testoni N et al. (2002) Clonal eosinophils are a morphologic hallmark of ETV6/ABL1 positive acute myeloid leukemia. Haematologica 87: 789–794PubMedGoogle Scholar
  76. [76]
    Haferlach T, Winkemann M, Nickenig C et al. (1997) Which compartments are involved in Philadelphia-chromosome positive chronic myeloid leukemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 97: 99–106PubMedGoogle Scholar
  77. [77]
    Gabbas AG, Li CY (1986) Acute nonlymphocytic leukemia with eosinophilic differentiation. Am J Hematol 21: 29–38PubMedGoogle Scholar
  78. [78]
    Delaunay J, Vey N, Leblanc T et al. (2003) Prognosis of inv (16) /t (16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 102: 462–469PubMedGoogle Scholar
  79. [79]
    Loffler H, Gassmann W, Haferlach T (1995) AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects. Leuk Lymphoma 18(Suppl 1): 61–63PubMedGoogle Scholar
  80. [80]
    Shelley WB, Parnes HM (1965) The absolute basophil count. JAMA 192: 368–370PubMedGoogle Scholar
  81. [81]
    Juhlin L (1963) Basophil leukocyte differential in blood and bone marrow. Acta Haematol 29: 89–95Google Scholar
  82. [82]
    Gilbert HS, Ornstein L (1975) Basophil counting with a new staining method using alcian blue. Blood 46: 279–286PubMedGoogle Scholar
  83. [83]
    Galli SJ, Dvorak AM, Dvorak HF (1984) Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy 34: 1–141PubMedGoogle Scholar
  84. [84]
    Brown SJ, Galli SJ, Gleich GJ, Askenase PW (1982) Ablation of immunity to Amblyomma americanum by anti-basophil serum: cooperation between basophils and eosinophils in expression of immunity to ectoparasites (ticks) in guinea pigs. J Immunol 129: 790–796PubMedGoogle Scholar
  85. [85]
    Athreya BH, Moser G, Raghavan TE (1975) Increased circulating basophils in juvenile rheumatoid arthritis. A preliminary report. Am J Dis Child 129: 935–937PubMedGoogle Scholar
  86. [86]
    Juhlin L (1963) Basophil leukocytes in ulcerative colitis. Acta Med Scand 173: 351–359Google Scholar
  87. [87]
    Gray AG, Boughton BJ, Burt DS, Struthers GR (1982) Basophils, histamine and gastric acid secretin in chronic myeloproliferative disorders. Br J Haematol 51: 117–123PubMedGoogle Scholar
  88. [88]
    Pieri L, Bogani C, Guglielmelli P et al. (2009) The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. Haematologica (Epub ahead of print)Google Scholar
  89. [89]
    Spiers AS, Bain BJ, Turner JE (1977) The peripheral blood in chronic granulocytic leukemia. Study of 50 untreated Philadelphia-positive cases. Scand J Haematol 18: 25–38PubMedGoogle Scholar
  90. [90]
    Goh KO, Anderson FW (1979) Cytogenetic studies in basophilic chronic myelocytic leukemia. Arch Pathol Lab Med 103: 288–290PubMedGoogle Scholar
  91. [91]
    Denburg JA, Browman G (1988) Prognostic implications of basophil differentiation in chronic myeloid leukemia. Am J Hematol 27: 110–114PubMedGoogle Scholar
  92. [92]
    Hasford J, Pfirrmann M, Hehlmann R et al. (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90: 850–858PubMedGoogle Scholar
  93. [93]
    Duchayne E, Demur C, Rubie H, Robert A, Dastugue N (1999) Diagnosis of acute basophilic leukemia. Leuk Lymphoma 32: 269–278PubMedGoogle Scholar
  94. [94]
    Lewis RA, Goetzl EJ, Wasserman SI, Valone FH, Rubin RH, Austen KF (1975) The release of four mediators of immediate hypersensitivity from human leukemic basophils. J Immunol 114: 87–92PubMedGoogle Scholar
  95. [95]
    Youman JD, Taddeini L, Cooper T (1973) Histamine excess symptoms in basophilic chronic granulocytic leukemia. Arch Intern Med 131: 560–562PubMedGoogle Scholar
  96. [96]
    Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A (2005) WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia 19: 313–317PubMedGoogle Scholar
  97. [97]
    Bohm J, Schaefer HE (2002) Chronic neutrophilic leukemia: 14 new cases of an uncommon myeloproliferative disease. J Clin Pathol 55: 862–864PubMedGoogle Scholar
  98. [98]
    Parry H, Cohen S, Schlarb JE et al. (1997) Smoking, alcohol consumption, and leukocyte counts. Am J Clin Pathol 107: 64–67PubMedGoogle Scholar
  99. [99]
    Schwartz J, Weiss ST (1994) Cigarette smoking and peripheral blood leukocyte differentials. Ann Epidemiol 4: 236–242PubMedGoogle Scholar
  100. [100]
    Satter EK, High WA (2008) Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol 25: 291–295PubMedGoogle Scholar
  101. [101]
    Merad M, Manz MG (2009) Dendritic cell homeostasis. Blood 113: 3418–3427PubMedGoogle Scholar
  102. [102]
    Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245–252PubMedGoogle Scholar
  103. [103]
    Allen CD, Cyster JG (2008) Follicular dendritic cell networks of primary follicles and germinal centers: phenotype and function. Semin Immunol 20: 14–25PubMedGoogle Scholar
  104. [104]
    Favara BE, Feller AC, Pauli M et al. (1997) Contemporary classification of histiocytic disorders. The WHO Committee on Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 29: 157–166PubMedGoogle Scholar
  105. [105]
    Rosai J, Dorfman RF (1969) Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol 87: 63–70PubMedGoogle Scholar
  106. [106]
    Gaitonde S (2007) Multifocal, extranodal sinus histiocytosis with massive lymphadenopathy: an overview. Arch Pathol Lab Med 131: 1117–1121PubMedGoogle Scholar
  107. [107]
    Mehraein Y, Wagner M, Remberger K et al. (2006) Parvovirus B19 detected in Rosai-Dorfman disease in nodal and extranodal manifestations. J Clin Pathol 59: 1320–1326PubMedGoogle Scholar
  108. [108]
    Foucar E, Rosai J, Dorfman R (1990) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol 7: 19–73PubMedGoogle Scholar
  109. [109]
    Foucar E, Rosai J, Dorfman RF (1984) Sinus histiocytosis with massive lymphadenopathy. An analysis of 14 deaths occurring in a patient registry. Cancer 54: 1834–1840PubMedGoogle Scholar
  110. [110]
    Pulsoni A, Anghel G, Falcucci P et al. (2002) Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review. Am J Hematol 69: 67–71PubMedGoogle Scholar
  111. [111]
    Sita G, Guffanti A, Colombi M, Ferrari A, Neri A, Baldini L (1996) Rosai-Dorfman syndrome with extranodal localizations and response to glucocorticoids: a case report. Haematologica 81: 165–167PubMedGoogle Scholar
  112. [112]
    Antonius JI, Farid SM, Baez-Giangreco A (1996) Steroid-responsive Rosai-Dorfman disease. Pediatr Hematol Oncol 13: 563–570PubMedGoogle Scholar
  113. [113]
    Baildam EM, Ewing CI, D’Souza SW, Stevens RF (1992) Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): response to acyclovir. J R Soc Med 85: 179–180PubMedGoogle Scholar
  114. [114]
    Lohr HF, Godderz W, Wolfe T et al. (1995) Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer 31A: 2427–2428Google Scholar
  115. [115]
    Palomera L, Domingo JM, Olave T, Romero S, Gutierrez M (1997) Sinus histiocytosis with massive lymphadenopathy: complete response to low-dose interferon-alpha. J Clin Oncol 15: 2176PubMedGoogle Scholar
  116. [116]
    Viraben R, Dupre A, Gorguet B (1988) Pure cutaneous histiocytosis resembling sinus histiocytosis. Clin Exp Dermatol 13: 197–199PubMedGoogle Scholar
  117. [117]
    Bhatia S, Nesbit ME Jr, Egeler RM, Buckley JD, Mertens A, Robison LL (1997) Epidemiologic study of Langerhans cell histiocytosis in children. J Pediatr 130: 774–784PubMedGoogle Scholar
  118. [118]
    Hamre M, Hedberg J, Buckley J et al. (1997) Langerhans cell histiocytosis: an exploratory epidemiologic study of 177 cases. Med Pediatr Oncol 28: 92–97PubMedGoogle Scholar
  119. [119]
    Stalemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter JI (2008) Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer 51: 76–81PubMedGoogle Scholar
  120. [120]
    Shahla A, Parvaneh V, Hossein HD (2004) Langerhans cells histiocytosis in one family. Pediatr Hematol Oncol 21: 313–320PubMedGoogle Scholar
  121. [121]
    Alston RD, Tatevossian RG, McNally RJ, Kelsey A, Birch JM, Eden TO (2007) Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer 48: 555–560PubMedGoogle Scholar
  122. [122]
    Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ (1999) Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 85: 2278–2290PubMedGoogle Scholar
  123. [123]
    Wladis EJ, Tomaszewski JE, Gausas RE (2008) Langerhans cell histiocytosis of the orbit 10 years after involvement at other sites. Ophthal Plast Reconstr Surg 24: 142–143PubMedGoogle Scholar
  124. [124]
    Henter JI, Tondini C, Pritchard J (2004) Histiocyte disorders. Crit Rev Oncol Hematol 50: 157–174PubMedGoogle Scholar
  125. [125]
    Slater JM, Swarm OJ (1980) Eosinophilic granuloma of bone. Med Pediatr Oncol 8: 151–164PubMedGoogle Scholar
  126. [126]
    Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F (1997) Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28: 9–14PubMedGoogle Scholar
  127. [127]
    Donadieu J, Rolon MA, Thomas C et al. (2004) Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study. J Pediatr 144: 344–350PubMedGoogle Scholar
  128. [128]
    Broadbent V, Gadner H, Komp DM, Ladisch S (1989) Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society. Med Pediatr Oncol 17: 492–495PubMedGoogle Scholar
  129. [129]
    Hadfield PJ, Birchall MA, Albert DM (1994) Otitis externa in Langerhans’ cell histiocytosis — the successful use of topical nitrogen mustard. Int J Pediatr Otorhinolaryngol 30: 143–149PubMedGoogle Scholar
  130. [130]
    Sheehan MP, Atherton DJ, Broadbent V, Pritchard J (1991) Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pediatr 119: 317–321PubMedGoogle Scholar
  131. [131]
    Sakai H, Ibe M, Takahashi H et al. (1996) Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient. J Dermatol 23: 42–46PubMedGoogle Scholar
  132. [132]
    Gadner H, Grois N, Arico M et al. (2001) A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 138: 728–734PubMedGoogle Scholar
  133. [133]
    Gadner H, Grois N, Potschger U et al. (2008) Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 111: 2556–2562PubMedGoogle Scholar
  134. [134]
    Pileri SA, Grogan TM, Harris NL et al. (2002) Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology 41: 1–29PubMedGoogle Scholar
  135. [135]
    Hornick JL, Jaffe ES, Fletcher CD (2004) Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 28: 1133–1144PubMedGoogle Scholar
  136. [136]
    Kairouz S, Hashash J, Kabbara W, McHayleh W, Tabbara IA (2007) Dendritic cell neoplasms: an overview. Am J Hematol 82: 924–928PubMedGoogle Scholar
  137. [137]
    Ferringer T, Banks PM, Metcalf JS (2006) Langerhans cell sarcoma. Am J Dermatopathol 28: 36–39PubMedGoogle Scholar
  138. [138]
    Misery L, Godard W, Hamzeh H et al. (2003) Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol 49: 527–529PubMedGoogle Scholar
  139. [139]
    Efune G, Sumer BD, Sarode VR, Wang HY, Myers LL (2009) Interdigitating dendritic cell sarcoma of the parotid gland: case report and literature review. Am J Otolaryngol 30: 264–268PubMedGoogle Scholar
  140. [140]
    Gaertner EM, Tsokos M, Derringer GA, Neuhauser TS, Arciero C, Andriko JA (2001) Interdigitating dendritic cell sarcoma. A report of four cases and review of the literature. Am J Clin Pathol 115: 589–597PubMedGoogle Scholar
  141. [141]
    Chera BS, Orlando C, Villaret DB, Mendenhall WM (2008) Follicular dendritic cell sarcoma of the head and neck: case report and literature review. Laryngoscope 118: 1607–1612PubMedGoogle Scholar
  142. [142]
    Abidi MH, Tove I, Ibrahim RB, Maria D, Peres E (2007) Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant. Am J Hematol 82: 932–933PubMedGoogle Scholar
  143. [143]
    Schwartz RH, Hayden GF, Rodriguez WJ, Sait T, Chhabra O, Golub J (1986) Leukocyte counts in children with acute otitis media. Pediatr Emerg Care 2: 10–14PubMedGoogle Scholar
  144. [144]
    Pouchot J, Sampalis JS, Beaudet F et al. (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70: 118–136Google Scholar
  145. [145]
    McBride JA, Dacie JV, Shapley R (1968) The effect of splenectomy on the leucocyte count. Br J Haematol 14: 225–231PubMedGoogle Scholar
  146. [146]
    Christensen RD, Hill HR (1987) Exercise-induced changes in the blood concentration of leukocyte populations in teenage athletes. Am J Pediatr Hematol Oncol 9: 140–142PubMedGoogle Scholar
  147. [147]
    Dale DC, Fauci AS, Guerry D, IV, Wolff SM (1975) Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 56: 808–813PubMedGoogle Scholar
  148. [148]
    Boggs DR, Joyce RA (1983) The hematopoietic effects of lithium. Semin Hematol 20: 129–138PubMedGoogle Scholar
  149. [149]
    dePalma L, Delgado P (1996) Clin Chem Acta 244: 83–90Google Scholar
  150. [150]
    Tanaka KR, Valentine WM (1960) NEJM 262: 912–918PubMedGoogle Scholar
  151. [151]
    Stinson RA, Mcphee J (1985) NEJM 312: 1642–1643PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2010

Authors and Affiliations

  • Thomas Melchardt
    • 1
  • Lukas Weiss
    • 1
  • Lisa Pleyer
    • 1
  • Daniel Neureiter
    • 1
  • Victoria Faber
    • 1
  • Richard Greil
    • 1
  1. 1.Universitätsklinik für Innere Medizin IIIParacelsus Medizinische PrivatuniversitätSalzburgAustria

Personalised recommendations